Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Hypertension
- Registration Number
- NCT00034307
- Lead Sponsor
- ICOS-Texas Biotechnology
- Brief Summary
This is a clinical research study designed to evaluate an investigational new medication called sitaxsentan for the treatment of pulmonary arterial hypertension (patients with NYHA functional class II, III or IV). The purpose of this study is to evaluate the safety and effectiveness of two different doses of sitaxsentan, compared to placebo (inactive treatment) for the treatment of pulmonary arterial hypertension. Patients who complete this trial may be eligible to take part in an extension trial (Protocol FPH01-X). Eligible patients who receive placebo in the 12-week study cross over to receive sitaxsentan for the extension trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 180
- NYHA Class II, III or IV
- 16 to 75 years of age
- Specific peak VO2 range
- PPH, PAH due to connective tissue disease or select congenital heart disease
- Qualifying cardiac catheterization
- History of CXR and qualifying pulmonary function test
- History of qualifying ventilation-perfusion lung scan
- History of qualifying echocardiogram
- Women of childbearing potential must use contraceptives
- Stable dose of corticosteroids if prescribed
- Significant lung disease
- Chronic liver disease
- Uncontrolled sleep apnea
- History of specific types of left heart disease
- Any disorder that compromises ability to give informed consent
- Uncontrolled sleep apnea
- Inability to perform bicycle exercise test
- On-going treatment with an experimental drug or device within the last 30 days
- HIV infection
- Specific liver dysfunction
- Chronic renal disease
- Pregnancy/Nursing
- Chronic active hepatitis B or C
- Chronic Flolan or Tracleer use within the last 30 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (26)
University of Southern California Hospital, Ambulatory Health Sciences
🇺🇸Los Angeles, California, United States
University of California, San Francisco
🇺🇸San Francisco, California, United States
Harbor-UCLA Medical Center
🇺🇸Torrance, California, United States
The Children's Hospital
🇺🇸Denver, Colorado, United States
University of Colorado/ Health Science Center
🇺🇸Denver, Colorado, United States
Emory University Hospital - McKelvey Lung Transplantation Center
🇺🇸Atlanta, Georgia, United States
Medical College of Georgia
🇺🇸Augusta, Georgia, United States
Dekalb Medical Center
🇺🇸Decatur, Georgia, United States
Rush Heart Institute, Center for Pulmonary Heart Disease, Rush-Presbyterian-St. Luke's Medical Center
🇺🇸Chicago, Illinois, United States
LSU - School of Medicine
🇺🇸New Orleans, Louisiana, United States
Scroll for more (16 remaining)University of Southern California Hospital, Ambulatory Health Sciences🇺🇸Los Angeles, California, United States